Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 103-111

  Pályi, István ^a   Kremmer, Tibor ^a   Kálnay, Adrienn ^a   Turi, Gizella ^a   Mihalik, Rudolf ^b   Bencsik, Katalin ^a   Boldizsár, Marìann ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b National Institute of Blood Transfusion   (Hungary)

Author keywords

Cell cycle; In vitro sensitivity; Methylacetylenic putrescine; Non apoptotic cell death; ODC activity; Polyamine metabolism

Indexed keywords

6 HEPTYNE 2,5 DIAMINE; ANTINEOPLASTIC AGENT; ORNITHINE DECARBOXYLASE; ORNITHINE DECARBOXYLASE INHIBITOR; POLYAMINE; PUTRESCINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL STRUCTURE; CELL VACUOLE; CLONOGENIC ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; POLYAMINE METABOLISM; PRIORITY JOURNAL;

EID: 0033036747     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00013     Document Type: Article

References (56)

1. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981; 19: 1-20.
2. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984; 53: 749-90.
3. Seiler N. Polyamines. J Chromatogr 1986; 379: 157-76.
4. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988; 48: 759-64.
5. Seiler N, Delcros JG, Moulinoux JP. Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 1996; 28: 843-61.
6. Scalabrino G, Ferioli ME. Polyamines in mammalian tumors. Adv Cancer Res 1981; 35: 151-268.
7. Horn Y, Real SL, Walach N, Lubich WP, Spigel L, Marton LJ. Further evidence for the use of polyamines as biochemical markers for malignant tumors. Cancer Res 1982; 42: 3248-51.
8. Russell DH. Clinical relevance of polyamines. CRC Crit Rev Clin Lab Sci 1983; 18: 261-311.
9. Bondy PK, Canellakis ZN. Polyamines and neoplasia: a review of present knowledge of their function and therapeutic potential. In: Davis W, Maltoni C, Tanneberger ST, eds. The control of tumour growth and its biological bases. Berlin: Akademie-Verlag 1983: 258-68.
10. Kremmer T, Selmeci L, Bardócz S, Holczinger L, Bálint S. Polyamine metabolism in P388 leukemia cells and in ascites tumor bearing mice. Exp Cell Biol 1984; 52: 279-85.
11. Horn Y, Beal SL, Walach N, Lubich WP, Spigel L, Marton LJ. Relationship of urinary polyamines to tumor activity and tumor volume in patients. Cancer Res 1984; 44: 4675-8.
12. Seiler N, Knödgen B, Bartholeyns J. Polyamine metabolism and polyamine excretion in normal and tumor bearing rodents. Anticancer Res 1985; 5: 371-8.
13. Seiler N, Sarhan S, Graufferl C, Jones R, Knödgen B, Moulinoux JP. Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 1990; 50: 5077-83.
14. Russell DH, Durie BGM. Polyamines as tumor markers, In: Boelsma E, Rümke Ph, eds. Tumor markers: impact and prospects, applied methods in oncology 2. Amsterdam: Elsevier-North Holland 1979: 45-60.
15. Heby O, Oredsson SM, Kanje M. Polyamine biosynthetic enzymes as targets in cancer chemotherapy. Adv Enz Reg 1984; 22: 243-64.
16. McCann PP, Pegg AE, Sjoerdsma A, eds. Inhibition of polyamine metabolism. Biological significance and basis for new therapies. New York: Academic Press 1987.
17. Levin VA, Chamberlain MC, Prados MD, et al. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumor. Cancer Treat Rep 1987; 75: 459-64.
18. Heston WDW. Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv 1991; 11: 217-38.
19. Quemener V, Blanchard Y, Chamaillard L, Havouis R, Cipolla B, Moulinoux JPh. Polyamine deprivation: a new tool in cancer treatment. Anticancer Res 1994; 14: 443-8.
20. Meyskens FL Jr, Emerson SS, Pelot D, et al. Dose-deescalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994; 86: 1122-30.
21. Meyskens F, Gerner E, Pelot D, et al. A randomized double-blind placebo-controlled phase IIb trial of difluoromethylornithine (DFMO) for colon cancer prevention. Proc Am Ass Cancer Res 1997; 38: 528.
22. 1 to S transition. Exp Cell Res 1981; 131: 209-16.
23. Sunkara PS, Chang CC, Prakash NJ, Lachmann PJ. Effect of inhibition of polyamine biosynthesis by DL-α-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo. Cancer Res 1985; 45: 4067-70.
24. Luk GD, Baylin SB. Anchorage dependency effects of difluoromethylornithine cytotoxicity in human lung carcinoma cells. Cancer Res 1986; 46: 1844-8.
25. Luk GD, Abeloff MD, McCann PP, Sjoerdsma A, Baylin SB. Long-term maintenance therapy of established human small cell variant lung carcinoma implants in athymic mice with a cyclic regimen of difluoromethylornithine. Cancer Res 1986; 46: 1849-53.
26. Seidenfeld J, Block AL, Komar KA, Naujokas MF. Altered cell cycle phase distributions in cultured human carcinoma cells partially depleted polyamines by treatment with difluoromethylornithine. Cancer Res 1986; 46: 47-53.
27. Kremmer T, Boldizsár M, Holczinger L. In vivo effect of DL-α-difluoromethylornithine (DFMO) on the polyamine and nucleotide phosphate metabolism in P388/S leukemia cells. Exp Cell Biol 1986; 54: 8-15.
28. Bakic M, Chan D, Freireich EJ, Marton LJ, Zwelling LA. Effect of polyamine depletion by α-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Cancer Res 1987; 47: 6437-43.
29. Kremmer T, Pályi I, Holczinger L, et al. Changes in the polyamine and nucleotide metabolism of P388 leukemia cells treated with DL-α-difluoromethylornithine in culture. Exp Cell Biol 1988; 56: 131-7.
30. Kremmer T, Pályi I, Daubner D, et al. Comparative studies on the polyamine metabolism and DFMO treatment of MCF-7 and MDA-MB-231 breast cancer cell lines and xenografts. Anticancer Res 1991; 11: 1807-14.
31. Lipton A, Harvey HA, Glenn J, et al. A phase I study of hepatic arterial infusion using difluoromethylornithine. Cancer 1989; 63: 433-7.
32. Boiko I, Mitchell MF, Hu W, Malpica A, Pandey D, Hittelman WN. High mean DNA content and EGFR expression predict poor response of CIN 3 lesions to chemoprevention by difluoromethylornithine (DFMO). Proc Am Ass Cancer Res 1997; 38: 262.
33. Danzin G, Casara P, Claverie N, Metcalf BW, Jung MJ. (2R,5R)-6-heptyne-2,5-diamine, an extremely potent inhibitor of mammalian ornithine decarboxylase. Biochem Biophys Res Commun 1983; 116: 237-43.
34. Bartholeyns J, Mamont P, Casara P. Antitumor properties of (2R,5R)-6-heptyne-2,5-diamine, a new potent enzyme-activated irreversible inhibitor of ornithine decarboxylase in rodents. Cancer Res 1984; 44: 1972-7.
35. Mamont PS, Siat M, Joder-Ohlenbusch AM, Bernhardt A, Casara P. Effects of (2R,5R)-6-heptyne-2,5-diamine, a potent inhibitor of L-ornithine decarboxylase, on rat hepatoma cells cultured in vitro. Eur J Biochem 1984; 142: 457-63.
36. Pera PJ, Kramer DL, Sufrin JR, Porter CW. Comparison of the biological effect of four irreversible inhibitors of ornithine decarboxylase in two murine lymphocytic leukemia cell lines. Cancer Res 1986; 46: 1148-54.
37. Milam KM, Deen DF, Marton LJ. Cell proliferation and polyamine metabolism in 9L cells treated with (2R,5R)-6-heptyne-2,5-diamine or α-difluoromethylornithine. Cell Tissue Kinet 1989; 22: 269-77.
38. Adlakha RC, Ashorn C, Wagle J, Nishioka K, Freireich EJ. Differential effects of (2R,5R)-6-heptyne-2,5 diamine, a potent inhibitor of polyamines on the cell cycle traverse of normal and transformed cells. Proc Am Ass Cancer Res 1989; 30: 586.
39. Sunkara PS, Baylin SB, Luk GD. Inhibitors of polyamine biosynthesis: cellular and in vivo effects of tumor proliferation. In: McCann PP, Pegg AE, Sjoerdsma A. eds. Inhibition of polyamine metabolism. Orlando: Academic Press 1987: 121-140.
40. McCloskey DE, Casero RA Jr, Woster PM, Davidson NE. Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res 1995; 55: 3233-6.
41. Pályi I. Survival responses to new cytostatic hexitols of P388 mouse and K562 human leukemia cells in vitro. Cancer Treat Rep 1986; 70: 279-84.
42. Pályi I, Péter I, Daubner D, Vincze B, Lorincz I. Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Archiv B Cell Pathol Mol Pathol 1993; 63: 263-9.
43. Shapiro HM. Practical flow cytometry. New York: Alan R Liss 1988.
44. Kvannes J., Flatmark T. Rapid and sensitive assay of ornithine decarboxylase activity by high-performance liquid chromatography of the o-phthalaldehyde derivative of putrescine. J Chromatogr 1987; 419: 291-5.
45. Kremmer T, Boldizsár M, Paulik E. Application of high-performance liquid Chromatographic methods in the monitoring of enzyme-targeted chemotherapy. Chromatographia 1988; 26: 423-8.
46. Shoemaker RH, Monks A, Alley MC, et al. Development of human tumor cell line panels for use in disease-oriented drug screening. In: Hall T, ed. Prediction of response to cancer chemotherapy. New York: Alan R Liss 1988: 265-85.
47. Van Putten LM. Are cell kinetic data relevant for the design of tumour chemotherapy schedules? Cell Tissue Kinet 1974; 7: 493-504.
48. 12-Bis(ethyl)spermine. Cancer Res 1993; 53: 2071-5.
49. Ask A, Persson L, Oredsson SM, Heby O. Synergistic antileukemic effect of two polyamine synthesis inhibitors. Host survival and cell-cycle kinetic analysis. Int J Cancer 1986; 37: 465-70.
50. Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 1966; 37: 233-45.
51. Clarke PGH. Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol 1990; 181: 195-213.
52. Levitzki G, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267: 1782-8.
53. Szende B, Kéri Gy, Szegedi Zs, et al. Tyrphostin induces non-apoptotic programmed cell death in colon tumor cell. Cell Biol Int 1995; 19: 903-11.
54. Packham G, Cleveland JL. C-Myc and apoptosis. Biochim Biophys Acta 1995; 1242: 11-28.
55. Coffino P, Poznanski A. Killer polyaminase? J Cell Biochem 1991; 45: 54-8.
56. Morris DR. New perspectives on ornithine decarboxylase regulation: Prevention of polyamine toxicity is the overriding theme. J Cell Biochem 1991; 46: 102-5.